Live Breaking News & Updates on Oncology Drug Development

Stay updated with breaking news from Oncology drug development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oncoinvent AS: Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors

Company adds experienced clinical development expert to its board of directors Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary ....

Jana Alfheim , Kostenloser Wertpapierhandel , Royh Larsen , Adrian Senderowicz , Jonas Einarson , Oncology Drug Development , Us National Cancer Institute , Morphosys Inc , Company Extraordinary , Puma Biotechnology Ltd , Division Of Oncology Products , Linear Energy Transfer , Team Leader , Non Executive Director , Extraordinary General , Regulatory Oncology , Chief Medical Officer , Medical Officer , Acting Team Leader , Oncology Products , Step Pharma , Puma Biotechnology , Chief Executive Officer ,

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

/PRNewswire/ Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with. ....

United States , Hong Kong , Juergen Wolf , Jeff Legos , Chan Al , Prnewswire Novartis , Biochim Biophys Acta , Jamie Bennett , Julie Masow , Sloan Simpson , American Joint Committee On Cancer , American Society Of Clinical Oncology , University Hospital Cologne , National Comprehensive Cancer Network Guidelines , American Cancer Society , Study Of Capmatinib , Virtual Scientific Program , Drug Administration , Foundation Medicine Inc , World Health Organization , Exchange Commission , Japanese Ministry Of Health , Head Of Oncology Drug Development , Nj Novartis Pharmaceuticals Corporation , American Society , Clinical Oncology ,

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved ....

United States , Hong Kong , Juergen Wolf , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Chan Al , Biochim Biophys Acta , Samir Shah , Mary Curtin Creaser , Julie Masow , Sloan Simpson , American Joint Committee On Cancer , American Society Of Clinical Oncology , University Hospital Cologne , Novartis External Communications , National Comprehensive Cancer Network Guidelines , American Cancer Society , Global Oncology Communications , Study Of Capmatinib , Virtual Scientific Program , Drug Administration , Foundation Medicine Inc , World Health Organization , Novartis Us External Communications , Exchange Commission ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC ....

United States , Hong Kong , Juergen Wolf , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Chan Al , Biochim Biophys Acta , Samir Shah , Mary Curtin Creaser , Julie Masow , Sloan Simpson , American Joint Committee On Cancer , American Society Of Clinical Oncology , University Hospital Cologne , Novartis External Communications , National Comprehensive Cancer Network Guidelines , American Cancer Society , Global Oncology Communications , Study Of Capmatinib , Virtual Scientific Program , Drug Administration , Foundation Medicine Inc , World Health Organization , Novartis Us External Communications , Exchange Commission ,

Calyx Welcomes Catalyst to the ACTIVATE CRO Partnership Program

Calyx Welcomes Catalyst to the ACTIVATE CRO Partnership Program
Synergistic offerings deliver successful early-phase oncology clinical trials.
News provided by
Share this article
Share this article
NOTTINGHAM, England, May 10, 2021 /PRNewswire/ Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that Catalyst Clinical Research will enter into a partnership with Calyx to leverage Calyx s Medical Imaging solution for their customers oncology trials.
John Blakeley, Chief Commercial Officer, Calyx
Calyx s proven imaging services complement Catalyst s expertise in executing complex oncology trials for biotech clients
A leading provider of clinical research services, Catalyst Clinical Research s full-service, niche oncology CRO solution is focused on next-generation cancer therapies. Catalyst Oncology offers skilled management of immuno-oncology a ....

John Blakeley , Andrew Zupnick , Catalyst Clinical Research , Novaquest Capital Management , Oncology Drug Development At Catalyst , Catalyst Oncology , Vice President , Oncology Drug Development , Chief Commercial Officer , Medical Imaging , Clinical Research , Catalyst Flex , ஜான் பிளேக்லி , வினையூக்கி மருத்துவ ஆராய்ச்சி , துணை ப்ரெஸிடெஂட் , புற்றுநோயியல் மருந்து வளர்ச்சி , தலைமை வணிகரீதியானது அதிகாரி , மருத்துவ இமேஜிங் , மருத்துவ ஆராய்ச்சி ,